Last updated on June 2019

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain


Brief description of study

The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg / norethisterone acetate (NETA) 0.5 mg) versus placebo, in the management of moderate to severe endometriosis-associated pain (EAP).

Detailed Study Description

This is a prospective, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of linzagolix administered orally once daily at doses of 75 mg alone and 200 mg in combination with low dose ABT (E2 1 mg/NETA 0.5 mg) versus placebo in the management of moderate to severe EAP in 450 women.

Eligible subjects who have completed the 6-month treatment period may enter a separate extension study for 6 additional months of active treatment (no placebo control). Subjects who do not continue in the extension study will enter a 6 month treatment-free follow-up phase.

Clinical Study Identifier: NCT03986944

Find a site near you

Start Over

718

Denver, CO United States
  Connect »

732

Lakewood, CO United States
  Connect »

750

Boynton Beach, FL United States
  Connect »

731

Orlando, FL United States
  Connect »

779

Orlando, FL United States
  Connect »

727

Atlanta, GA United States
  Connect »

712

Fall River, MA United States
  Connect »

707

Albuquerque, NM United States
  Connect »

744

Jenkintown, PA United States
  Connect »

771

Austin, TX United States
  Connect »

763

Fort Worth, TX United States
  Connect »

737

League City, TX United States
  Connect »

710

Schertz, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.